search
Back to results

Monitoring Tissue Perfusion in Critically Ill or High-risk Surgical Patients (STEP UP)

Primary Purpose

High-risk Surgical Patients

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
IKORUS UP system
Sponsored by
Advanced Perfusion Diagnostics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for High-risk Surgical Patients

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  1. 18 years of age or more,
  2. Male or female,
  3. High-Risk surgical patient,
  4. Life expectancy expected to exceed 72 hours,
  5. Willing to participate and signed informed consent,
  6. Affiliation to the French social security system.

Non inclusion criteria:

  1. Pregnant or lactating woman,
  2. History of recent urological surgery (bladder surgery, prostate surgery…),
  3. Known stricture or "impossible insertion" last hospitalization,
  4. Traumatic injury to the lower urinary tract,
  5. History of radiotherapy of pelvic or genital area,
  6. Genital malformation (Hypospadias…).

Sites / Locations

  • CHU Estaing
  • Lyon Sud Hospital
  • Hopital Nord Marseille
  • Hospital Saint Louis

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

IKORUS UP

Arm Description

Outcomes

Primary Outcome Measures

Incidence of complications
Complications rate: Injury during insertion; Bleeding; Infection; Pain; Discomfort.

Secondary Outcome Measures

Applicability of the procedure
Evaluation of applicability (compared to a standard Foley catheter): questionnaire for the nurse and/or the physician.
Signal acquisition
Duration of useable signal acquisition (duration of perfusion index computation)
Effect of the position of the sensor
Quality of signal according to sensor position (proximal/distal)
Quality of the signal
Assessment of signal Quality, including Signal-to-noise ratio
Evolution of mean arterial pressure
Measures of hemodynamic /metabolic parameters: mean arterial pressure (MAP)
Evolution of SpO2
Measures of hemodynamic /metabolic parameters: SpO2
Evolution of SVO2
Measures of hemodynamic /metabolic parameters: SVO2
Evolution of lactates dosages
Measures of hemodynamic /metabolic parameters: lactactes
Evolution of cardiac outputs
Measures of hemodynamic /metabolic parameters: cardiac output
Evolution of central venous pressure
Measures of hemodynamic /metabolic parameters: central venous pressure (CVP)
Evolution of catecholamine infusions levels
Measures of hemodynamic /metabolic parameters: catecholamine infusions levels
Rate of resuscitation events
Measures of hemodynamic or metabolic parameters: resuscitation events

Full Information

First Posted
January 12, 2018
Last Updated
May 17, 2019
Sponsor
Advanced Perfusion Diagnostics
Collaborators
CEISO
search

1. Study Identification

Unique Protocol Identification Number
NCT03410069
Brief Title
Monitoring Tissue Perfusion in Critically Ill or High-risk Surgical Patients
Acronym
STEP UP
Official Title
Monitoring Tissue Perfusion in Critically Ill or High-risk Surgical Patients: a Pilot Clinical Study To Evaluate the aPplicability and the Safety of Urethral Perfusion Measurement With the IKORUS System
Study Type
Interventional

2. Study Status

Record Verification Date
May 2019
Overall Recruitment Status
Completed
Study Start Date
August 3, 2018 (Actual)
Primary Completion Date
May 7, 2019 (Actual)
Study Completion Date
May 7, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Advanced Perfusion Diagnostics
Collaborators
CEISO

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Circulatory shock is defined as an imbalance between oxygen supply and/or impaired oxygen use to maintain organ function. With growing evidence of lack of correlation between macro- and micro-circulation, use of "Whole Body" markers such as blood pressure (BP) or Lactates are often insufficient to assess the severity of the oxygen debt and/or tissue hypoperfusion. Thus, an approach incorporating tissue-perfusion based endpoints would represent a significant step up to guide optimal resuscitation of critically-ill patients and to reduce complications in high-risk surgery. Current monitoring techniques, that complement systemic hemodynamics by focusing on regional perfusion, still lack the required user-friendliness and/or clinical relevance to be routinely used at bedside. Therefore, assessment of the adequacy of tissue perfusion and oxygenation is suboptimal, and implementation of the above-mentioned approaches of resuscitation is still a challenge. Urethral perfusion is likely to be early and significantly impaired during low-flow states and thus represents a good "candidate" as a surrogate site to assess the perfusion of visceral organs. Besides, urethral mucosa can be investigated in a less invasive and simpler manner than "deeper" organs. Nowadays, no practical methods or devices are available to monitor perfusion in the pelvic area. Thus, recent development of a new monitoring device of urethral perfusion could fill this need and enable enhanced management of patients in Intensive Care Units (ICU) and Operating Rooms (OR). The device consists of a modified Foley catheter equipped with a photoplethysmographic sensor: the IKORUS UP probe. The probe will be used by intensivists or anesthesiologists on high-risk surgical patients, i.e. patients with comorbidities undergoing major vascular, thoracic and/or abdominal surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
High-risk Surgical Patients

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
IKORUS UP
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
IKORUS UP system
Intervention Description
Continuous assessment of the urethral microcirculation
Primary Outcome Measure Information:
Title
Incidence of complications
Description
Complications rate: Injury during insertion; Bleeding; Infection; Pain; Discomfort.
Time Frame
28 days
Secondary Outcome Measure Information:
Title
Applicability of the procedure
Description
Evaluation of applicability (compared to a standard Foley catheter): questionnaire for the nurse and/or the physician.
Time Frame
28 days
Title
Signal acquisition
Description
Duration of useable signal acquisition (duration of perfusion index computation)
Time Frame
28 days
Title
Effect of the position of the sensor
Description
Quality of signal according to sensor position (proximal/distal)
Time Frame
28 days
Title
Quality of the signal
Description
Assessment of signal Quality, including Signal-to-noise ratio
Time Frame
28 days
Title
Evolution of mean arterial pressure
Description
Measures of hemodynamic /metabolic parameters: mean arterial pressure (MAP)
Time Frame
28 days
Title
Evolution of SpO2
Description
Measures of hemodynamic /metabolic parameters: SpO2
Time Frame
28 days
Title
Evolution of SVO2
Description
Measures of hemodynamic /metabolic parameters: SVO2
Time Frame
28 days
Title
Evolution of lactates dosages
Description
Measures of hemodynamic /metabolic parameters: lactactes
Time Frame
28 days
Title
Evolution of cardiac outputs
Description
Measures of hemodynamic /metabolic parameters: cardiac output
Time Frame
28 days
Title
Evolution of central venous pressure
Description
Measures of hemodynamic /metabolic parameters: central venous pressure (CVP)
Time Frame
28 days
Title
Evolution of catecholamine infusions levels
Description
Measures of hemodynamic /metabolic parameters: catecholamine infusions levels
Time Frame
28 days
Title
Rate of resuscitation events
Description
Measures of hemodynamic or metabolic parameters: resuscitation events
Time Frame
28 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: 18 years of age or more, Male or female, High-Risk surgical patient, Life expectancy expected to exceed 72 hours, Willing to participate and signed informed consent, Affiliation to the French social security system. Non inclusion criteria: Pregnant or lactating woman, History of recent urological surgery (bladder surgery, prostate surgery…), Known stricture or "impossible insertion" last hospitalization, Traumatic injury to the lower urinary tract, History of radiotherapy of pelvic or genital area, Genital malformation (Hypospadias…).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bernard Allaouchiche, Prof
Organizational Affiliation
Hospices Civils de Lyon
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU Estaing
City
Clermont-Ferrand
ZIP/Postal Code
63003
Country
France
Facility Name
Lyon Sud Hospital
City
Lyon
ZIP/Postal Code
69310
Country
France
Facility Name
Hopital Nord Marseille
City
Marseille
ZIP/Postal Code
13015
Country
France
Facility Name
Hospital Saint Louis
City
Paris
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31691897
Citation
Depret F, Leone M, Duclos G, Futier E, Montagne M, Legrand M, Allaouchiche B. Monitoring tissue perfusion: a pilot clinical feasibility and safety study of a urethral photoplethysmography-derived perfusion device in high-risk patients. J Clin Monit Comput. 2020 Oct;34(5):961-969. doi: 10.1007/s10877-019-00414-9. Epub 2019 Nov 6.
Results Reference
derived

Learn more about this trial

Monitoring Tissue Perfusion in Critically Ill or High-risk Surgical Patients

We'll reach out to this number within 24 hrs